Press Releases Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 03:15:32 2026-01-22 pm EST			5-day change	1st Jan Change
1,092.70 ^USD	+1.31%		+5.45%	+1.36%

06:04am	Many patients may keep off lost pounds after stopping a GLP-1, US data suggests	RE
Jan. 21	Dr Reddy's gets regulatory nod to sell generic Ozempic in India, targets 12 million pens in first year	RE

Press Releases

10:02am	ELI LILLY AND COMPANY Scott+Scott Attorneys at Law LLP Investigates Eli Lilly and Company’s Directors and Officers for Breach of Fiduciary Duties – LLY	BU
Jan. 21	Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement	PR
Jan. 20	Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer	PR
Jan. 13	Popular weight-loss drugs shouldn't carry suicide warnings, FDA says	AQ
Jan. 12	Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets	AQ
Jan. 12	Class Action Pursued Concerning Safety Defects With GLP-1 Drugs Mounjaro, Trulicity, & Zepbound	AQ
Jan. 08	Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX	PR
Jan. 08	Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight	PR
Jan. 06	Novo Nordisk launches weight-loss pill Wegovy in the United States	AQ
Dec. 18	Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial	PR
Dec. 16	Lilly to participate in J.P. Morgan Healthcare Conference	PR
Dec. 12	Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer	PR
Dec. 11	Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial	PR
Dec. 09	Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama	PR
Dec. 09	Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL	PR
Dec. 08	Lilly declares first-quarter 2026 dividend	PR
Dec. 08	GLP-1 Agonists Market: Driving Innovation and Growth in Metabolic and Cardiovascular Care	AQ
Dec. 08	Carolyn Bertozzi returns to Lilly board of directors	PR
Dec. 07	Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)	PR
Dec. 03	Eli Lilly and : Lilly and IU to expand access to clinical trials and latest innovative treatments for Hoosiers	PU
Dec. 03	U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor	PR
Dec. 02	Lilly lowers the price of Zepbound single-dose vials	AQ
Nov. 26	BMO Launches New CDRs With Exposure to U.S. Stocks Including Microsoft, Eli Lilly, Exxon, Chevron and Robinhood	AQ
Nov. 24	Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium	PR
Nov. 24	Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Lilly Cuts Prices for Cash Buyers of Weight-Loss Drug Zepbound

December 01, 2025 at 10:39 am EST

Is it back to square one for Eli Lilly?

August 07, 2025 at 11:20 am EDT